# China Anti VEGF Market > China Anti-VEGF Market Research Report: Size, Share, Trend Analysis By Product (Eylea, Lucentis, Beovu) and By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-Related Macular Degeneration) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.28% - **2024:** $ 1,948.8 Million - **2025:** $ 2,032.21 Million - **2035:** $ 3,089.2 Million - **Key Players:** Regeneron Pharmaceuticals (US), Roche Holding (CH), Novartis (CH), Bayer AG (DE), Pfizer Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Santen Pharmaceutical (JP) **Report ID:** MRFR/HC/50415-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-anti-vegf-market-52173 --- ## Market Summary ## **China Anti-VEGF Market Overview** ### As per MRFR analysis, the China Anti-VEGF Market Size was estimated at 1.87 (USD Billion) in 2023.The China Anti-VEGF Market Industry is expected to grow from 1.95(USD Billion) in 2024 to 3.36 (USD Billion) by 2035. The China Anti-VEGF Market CAGR (growth rate) is expected to be around 5.071% during the forecast period (2025 - 2035). ### **Key China Anti-VEGF Market Trends Highlighted** The China Anti-VEGF market is experiencing substantial growth as a result of the rising incidence of retinal diseases, including diabetic retinopathy and age-related macular degeneration. An increased demand for innovative treatments has been generated by the increase in eye disorders in China, which the ageing population and rapid urbanization have exacerbated. Key market drivers that are driving the adoption of Anti-VEGF therapies include the government's initiatives to enhance healthcare access, which include reforms in the healthcare system and an increase in funding for eye care. Additionally, the market has been bolstered by the recent regulatory approvals of new anti-VEGF agents, which provide patients with a broader range of options. The development of biosimilars presents opportunities for the provision of cost-effective alternatives to the branded therapies that are currently available. Pharmaceutical companies are increasingly emphasizing research and development of innovative anti-VEGF treatments in response to the increasing prevalence of eye diseases. This initiative is establishing a path to address unmet market requirements. The potential for groundbreaking innovations in this field is being realized through collaborative endeavors between pharmaceutical firms and healthcare providers, which are gathering momentum. In recent years, there has been a growing emphasis on patient-centric approaches, with initiatives that are designed to inform patients about retinal diseases and treatment options.Additionally, the development of telemedicine services in China is enabling more effective patient-provider communication, which in turn enables the provision of timely diagnosis and treatment. In general, these trends suggest a dynamic shift in the anti-VEGF landscape in China, which is fostering a more proactive approach to eye care management and expanding access to essential therapies. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **China Anti-VEGF Market Drivers** ### **Rising Prevalence of Eye Diseases** The increasing prevalence of age-related macular degeneration (AMD) and [diabetic retinopathy](../../../reports/diabetic-retinopathy-market-5792) in China is a significant driver of the China Anti-VEGF Market Industry. According to data from the National Health Commission of the People's Republic of China, the incidence rate of AMD has reached approximately 2.3% among the elderly population. This translates to nearly 5 million people affected, highlighting a growing demand for effective treatment options like Anti-VEGF therapies. Moreover, with the aging population in China expected to exceed 300 million by 2025, the need for anti-VEGF medications is likely to rise substantially. Established organizations such as the Chinese Ophthalmological Society are actively promoting awareness about these conditions, thereby enhancing the market growth potential. ### **Advancements in Drug Formulations** Innovations in drug formulations are significantly boosting the China Anti-VEGF Market Industry. Recent developments have led to the creation of long-acting anti-VEGF agents that enhance patient compliance and reduce treatment frequency. For instance, a new formulation capable of delivering therapeutic effects for up to six months has been introduced by leading pharmaceutical companies in collaboration with local research institutions. The Chinese State Administration for Market Regulation has been supportive of these innovations by expediting the approval processes for breakthrough therapies, thereby encouraging companies to invest in Research and Development (R&D). This trend is expected to not only improve patient outcomes but also drive market growth. ### **Government Initiatives to Support Healthcare Innovation** The Chinese government has launched several initiatives aimed at bolstering healthcare innovation, which is instrumental to the growth of the China Anti-VEGF Market Industry. Policies such as the Healthy China 2030 initiative emphasize the need for advanced medical treatments, including anti-VEGF therapies. Additionally, the government has allocated increased funding for healthcare technology and R&D, projected to reach 6% of GDP by 2025. This commitment to healthcare not only supports the introduction of new therapies but also incentivizes public and private sector partnerships, further fueling market expansion in the Anti-VEGF space. ### **Increasing Awareness and Screening Programs** There is a significant increase in awareness surrounding eye diseases and the importance of early detection in China. Campaigns led by organizations such as the China National Blindness Prevention and Rehabilitation Program have reportedly led to a rise in eye health screenings, with nearly 23 million screenings conducted across the country in the past year. These initiatives have resulted in earlier diagnoses of conditions treatable with anti-VEGF medications. The heightened awareness drives demand for these therapies as more patients seek treatment options upon receiving a diagnosis, leading to a positive impact on the overall market growth of the China Anti-VEGF Market Industry. ## **China Anti-VEGF Market Segment Insights** ### **Anti-VEGF Market Product Insights** The China Anti-VEGF Market is witnessing notable dynamics driven by the increasing prevalence of retinal diseases and the growing aging population in the nation. Anti-VEGF therapies have become pivotal in managing conditions like age-related macular degeneration and diabetic retinopathy. Within this market, Eylea, Lucentis, and Beovu play significant roles, with Eylea being particularly recognized for its efficacy and once-a-month administration, appealing to patients seeking convenience and potentially improving adherence to treatment protocols. Lucentis has established itself as a cornerstone in the treatment for wet AMD and has a long history of clinical use, underpinning its reputation and reliability among healthcare professionals in China. Meanwhile, Beovu is gaining attention for its novel dosing schedule, offering an alternative treatment option that can improve patient experience and outcomes over time. The increasing investment in healthcare infrastructure and the focus on improving access to advanced therapies further enhance the prospects for these products in the Chinese market.Overall, the China Anti-VEGF market segmentation reveals a competitive landscape filled with opportunities as advancements in drug formulations and delivery methods stimulate market growth and address unmet medical needs in the population. Additionally, as healthcare policies in China evolve, the focus on affordable access to quality healthcare positions these anti-VEGF products as vital components in the fight against vision-threatening diseases. With rising awareness about eye health and the establishment of specialized ophthalmology centers across urban and rural areas, the prominence of these anti-VEGF therapies is set to increase, marking a transformative phase for the overall healthcare industry in China. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Anti-VEGF Market Disease Insights** The China Anti-VEGF Market focuses significantly on diseases that affect vision, with several prevalent conditions under its umbrella. Macular Edema presents a considerable challenge, often leading to vision impairment, as it involves the swelling of the macula due to fluid retention. Diabetic Retinopathy is a significant concern within diabetes management in China, affecting millions and driving the demand for effective treatments. Retinal Vein Occlusion is characterized by blocked retinal veins, which may result in severe vision loss, making timely intervention essential.Age-Related Macular Degeneration remains a leading cause of vision loss among the elderly population, exacerbated by an aging demographic in China. The importance of these diseases lies not only in their impact on individuals' quality of life but also in the escalating healthcare costs associated with their management, driving innovation and development within the China Anti-VEGF Market. Each of these conditions is critical, representing a substantial burden on both patients and the healthcare system, thereby contributing to the growth of the market as new treatment options emerge to address these vision-threatening diseases. ## **China Anti-VEGF Market Key Players and Competitive Insights** The China Anti-VEGF Market is characterized by a competitive landscape driven by the increasing prevalence of retinal diseases, the necessity for advanced therapeutic solutions, and a growing pool of patients requiring treatment. With a significant uptick in investments directed towards biotechnology and pharmaceuticals, the market is witnessing an evolution in treatment modalities aimed at combating conditions such as age-related macular degeneration and diabetic retinopathy. Numerous players are vying for market share, focusing on both innovation and meeting the regulatory requirements laid out by the Chinese healthcare authorities. The dynamic environment is primarily propelled by the need for efficient and effective drug therapies, alongside collaborations, partnerships, and mergers that seek to enhance product offerings and distribution networks. Sihuan Pharmaceutical Holdings Group has established a notable presence in the China Anti-VEGF Market through its strategic focus on developing innovative medicines tailored to ocular conditions. Its strength lies in robust research and development capabilities that enable the company to push boundaries and deliver effective treatments in a timely manner. Sihuan’s commitment to high-quality manufacturing processes and adherence to regulatory standards bolsters its reputation within the industry while also ensuring that it meets the diverse needs of Chinese patients. With an expansive distribution network across the country, the company has solidified its footprint, enhancing accessibility for patients in need of anti-VEGF therapies and establishing itself as a credible entity in the ophthalmic pharmaceutical sector. Regeneron Pharmaceuticals has made significant advancements in the China Anti-VEGF Market, particularly with its flagship product aimed at treating various retinal diseases. The company’s market presence is reinforced by its well-established reputation for research and innovation in the biological therapeutics space. Regeneron has strategically aligned itself with local stakeholders and authorities, enhancing its ability to penetrate the market effectively. Their strengths include unique product offerings that cater specifically to the demands of patients suffering from retinal conditions, bolstered by ongoing clinical trials aimed at expanding treatment indications. The company’s commitment to maintaining a competitive edge is evident through ongoing collaborations and potential mergers aimed at fostering growth and improving patient outcomes throughout China, thereby asserting its role as a leading player in the anti-VEGF therapy domain. ### **Key Companies in the China Anti-VEGF Market Include** ### **China Anti-VEGF Market Industry Developments** Recent developments in the China Anti-VEGF Market indicate significant activity and growth. In November 2021, Sihuan Pharmaceutical Holdings Group received marketing authorization for a new anti-VEGF drug, enhancing its portfolio within the Ophthalmology space. Major players such as Novartis and Roche continue to compete aggressively, particularly in the treatment of age-related macular degeneration, with Roche reporting a substantial increase in sales driven by their leading Anti-VEGF therapies in early 2023. In terms of mergers and acquisitions, Amgen and Beijing Mabworks Biotech engaged in a cooperative venture in August 2022 focused on developing innovative monoclonal antibodies. This strategic partnership aims to expand their market share in China. Additionally, Jiangsu Hengrui Medicine has recently invested heavily in the Research and Development of novel anti-VEGF treatments, which aligns with the surge in demand amidst the increasing prevalence of retinal diseases in the country. The Chinese market is forecasted to rise notably, reflecting a growing investment in innovative healthcare solutions and increased access to therapies for patients suffering from various ocular conditions. Overall, the landscape in China’s Anti-VEGF market remains dynamic, driven by both domestic innovation and collaborations with international firms. ## **China Anti-VEGF Market Segmentation Insights** ### **Anti-VEGF Market Product Outlook** ### **Anti-VEGF Market Disease Outlook** ## Market Drivers ### Increasing Aging Population The anti-VEGF market in China is experiencing growth due to the increasing aging population. As individuals age, they become more susceptible to ocular diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. This demographic shift is projected to lead to a higher demand for anti-VEGF therapies, which are essential in managing these conditions. According to recent statistics, the population aged 60 and above is expected to reach 400 million by 2040, representing a significant portion of the market. The anti vegf market must adapt to this demographic trend by ensuring accessibility and affordability of treatments for older patients, thereby potentially increasing market penetration and revenue generation. ### Rising Healthcare Expenditure China's rising healthcare expenditure is a crucial driver for the anti vegf market. The government has been increasing its investment in healthcare infrastructure and services, aiming to provide better access to advanced medical treatments. In 2025, healthcare spending is projected to reach approximately 7.5% of GDP, which translates to over $1 trillion. This increase in funding is likely to enhance the availability of anti-VEGF therapies, as hospitals and clinics expand their offerings. Furthermore, the anti vegf market could benefit from improved reimbursement policies, making these treatments more accessible to patients. As healthcare expenditure continues to rise, the market is expected to grow in tandem, driven by increased patient demand and improved treatment options. ### Supportive Regulatory Environment A supportive regulatory environment in China is fostering growth in the anti vegf market. The government has been implementing policies aimed at expediting the approval process for innovative therapies, including anti-VEGF agents. This regulatory support is crucial for encouraging pharmaceutical companies to invest in research and development, ultimately leading to a broader range of treatment options for patients. In recent years, the National Medical Products Administration (NMPA) has streamlined its approval processes, which may result in faster market entry for new therapies. The anti vegf market stands to benefit from these regulatory changes, as they could enhance competition and drive down costs, making treatments more accessible to the population. ### Growing Awareness of Ocular Health The growing awareness of ocular health among the Chinese population is driving the anti vegf market. Public health campaigns and educational initiatives are increasingly informing individuals about the risks associated with ocular diseases and the importance of early detection and treatment. This heightened awareness is likely to lead to more patients seeking medical advice and treatment options, thereby increasing the demand for anti-VEGF therapies. The anti vegf market must capitalize on this trend by engaging in outreach programs and partnerships with healthcare providers to promote awareness. As more individuals recognize the significance of maintaining ocular health, the market is expected to expand, driven by an influx of patients seeking effective treatments. ### Technological Advancements in Treatment Technological advancements in treatment methodologies are significantly influencing the anti vegf market in China. Innovations in drug delivery systems, such as sustained-release formulations and gene therapy, are enhancing the efficacy and safety profiles of anti-VEGF agents. These advancements not only improve patient outcomes but also reduce the frequency of administration, which is a critical factor for patient compliance. The anti vegf market is likely to see a shift towards these novel therapies, as they offer potential benefits over traditional treatments. As research and development continue to progress, the market may witness the introduction of new products that could reshape treatment paradigms and expand the patient base. ## Future Outlook The [Anti VEGF Market](https://www.marketresearchfuture.com/reports/anti-vegf-market-21963) in China is projected to grow at a 4.28% CAGR from 2025 to 2035, driven by increasing prevalence of retinal diseases and advancements in drug formulations. **New opportunities:** - Development of biosimilars to enhance market access and affordability. - Expansion of telemedicine platforms for remote patient monitoring and consultations. - Investment in localized manufacturing to reduce costs and improve supply chain efficiency. By 2035, the anti-VEGF market is expected to achieve substantial growth, driven by innovation and strategic investments. ## Segment Insights ### By Product: Eylea (Largest) vs. Beovu (Fastest-Growing) In the China anti-VEGF market, Eylea currently holds the largest market share, consistently outperforming its competitors, Lucentis and Beovu. This dominance can be attributed to its robust clinical efficacy and established brand presence, appealing to healthcare providers and patients alike. Lucentis, while significant, is gradually being overshadowed by emerging options, reflecting the competitive landscape. The growth trends indicate a compelling shift towards newer products like Beovu, which is recognized for its innovative administration and potential benefits over traditional treatments. The increasing prevalence of conditions treated by anti-VEGF therapies, coupled with advancements in drug formulations, drives the overall market forward. The emergence of biosimilars and extended-release formulations further enhances competition and growth potential in this sector. Eylea (Dominant) vs. Beovu (Emerging) Eylea, as the dominant player in the China anti vegf market, is known for its efficacy in treating age-related macular degeneration and diabetic macular edema. Its formulation offers both convenience and effectiveness, maintaining a strong patient adherence rate. In contrast, Beovu is an emerging option, gaining traction due to its differentiated dosing regimen and improved patient outcomes in clinical trials. It appeals to a market increasingly receptive to novel therapies that promise better convenience and reduced treatment burden. As both products continue to compete, their distinct characteristics position them uniquely within this dynamic landscape, showcasing the evolving preferences of healthcare professionals and patients. ### By Disease: Age-Related Macular Degeneration (Largest) vs. Diabetic Retinopathy (Fastest-Growing) In the China anti-VEGF market, Age-Related Macular Degeneration (AMD) holds the largest share, reflecting its significant prevalence among the aging population. Following closely, Diabetic Retinopathy (DR) is emerging as the fastest-growing segment, driven by the increasing incidence of diabetes across the country. Macular Edema and Retinal Vein Occlusion represent smaller shares, but they are critical segments that together support the overall market dynamics. The growth trends for AMD remain stable due to established treatment protocols and awareness, while DR is growing rapidly as healthcare providers emphasize early intervention. Factors such as rising diabetes prevalence, increased awareness of eye health, and advancements in anti-VEGF therapies are driving the expansion of these segments, particularly in urban areas where healthcare access is improving. Age-Related Macular Degeneration (Dominant) vs. Diabetic Retinopathy (Emerging) Age-Related Macular Degeneration (AMD) is characterized by its significant contribution to vision impairment in older adults, maintaining a dominant position in the China anti vegf market. The rise in the elderly demographic coupled with the development of effective anti-VEGF therapies solidifies its market presence. On the other hand, Diabetic Retinopathy (DR) is emerging rapidly due to the alarming increase in diabetes cases. DR requires timely management and intervention, making it a high priority for healthcare providers. This segment is witnessing innovations in treatment methodologies which are enhancing patient outcomes. Both segments are crucial, but their differing target demographics and treatment approaches highlight the diversity within the anti-VEGF therapy market. ## Competitive Benchmarking The anti-VEGF market in China is characterized by a dynamic competitive landscape, driven by increasing prevalence of retinal diseases and a growing aging population. Key players such as Regeneron Pharmaceuticals (US), Roche Holding (CH), and Novartis (CH) are strategically positioned to leverage innovation and expand their market presence. Regeneron Pharmaceuticals (US) focuses on enhancing its product portfolio through continuous research and development, while Roche Holding (CH) emphasizes strategic partnerships to bolster its therapeutic offerings. Novartis (CH) is actively pursuing regional expansion, particularly in underserved markets, which collectively shapes a competitive environment that is both collaborative and competitive.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to thrive, while larger companies consolidate their market share through strategic acquisitions and partnerships. In October Regeneron Pharmaceuticals (US) announced a collaboration with a leading Chinese biotech firm to develop a novel anti-VEGF therapy tailored for the Asian market. This strategic move is likely to enhance Regeneron's foothold in China, allowing it to tap into local expertise and accelerate the development of region-specific treatments. Such collaborations may also facilitate faster regulatory approvals, thereby improving market access. In September Roche Holding (CH) launched a new digital platform aimed at improving patient engagement and adherence to anti-VEGF therapies. This initiative underscores Roche's commitment to integrating technology into its treatment protocols, potentially leading to better patient outcomes and increased market share. The digital transformation strategy reflects a broader trend within the industry, where companies are leveraging technology to enhance service delivery and patient management. In August Novartis (CH) completed the acquisition of a smaller firm specializing in gene therapy for retinal diseases. This acquisition is indicative of Novartis's strategy to diversify its portfolio and invest in innovative treatment modalities. By integrating gene therapy into its offerings, Novartis positions itself at the forefront of cutting-edge treatments, which may redefine competitive dynamics in the anti-VEGF market. As of November current trends in the anti-VEGF market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and enhancing operational efficiencies. The focus appears to be shifting from price-based competition to differentiation through technological advancements and reliable supply chains. This evolution suggests that companies that prioritize innovation and adaptability will likely emerge as leaders in the anti-VEGF market. ## Recent News & Developments Recent developments in the China Anti-VEGF Market indicate significant activity and growth. In November 2021, Sihuan Pharmaceutical Holdings Group received marketing authorization for a new anti-VEGF drug, enhancing its portfolio within the Ophthalmology space. Major players such as Novartis and Roche continue to compete aggressively, particularly in the treatment of age-related macular degeneration, with Roche reporting a substantial increase in sales driven by their leading Anti-VEGF therapies in early 2023. In terms of mergers and acquisitions, Amgen and Beijing Mabworks Biotech engaged in a cooperative venture in August 2022 focused on developing innovative monoclonal antibodies. This strategic partnership aims to expand their market share in China. Additionally, Jiangsu Hengrui Medicine has recently invested heavily in the Research and Development of novel anti-VEGF treatments, which aligns with the surge in demand amidst the increasing prevalence of retinal diseases in the country. The Chinese market is forecasted to rise notably, reflecting a growing investment in innovative healthcare solutions and increased access to therapies for patients suffering from various ocular conditions. Overall, the landscape in China’s Anti-VEGF market remains dynamic, driven by both domestic innovation and collaborations with international firms. ## Report Scope | MARKET SIZE 2024 | 1948.8(USD Million) | | --- | --- | | MARKET SIZE 2025 | 2032.21(USD Million) | | MARKET SIZE 2035 | 3089.2(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.28% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Regeneron Pharmaceuticals (US), Roche Holding (CH), Novartis (CH), Bayer AG (DE), Pfizer Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Santen Pharmaceutical (JP) | | Segments Covered | Product, Disease | | Key Market Opportunities | Emerging biologics and personalized therapies drive growth in the anti vegf market. | | Key Market Dynamics | Rising demand for innovative anti-VEGF therapies driven by increasing prevalence of retinal diseases in China. | | Countries Covered | China | ## Frequently Asked Questions **Q: What was the overall valuation of the anti-VEGF market in China in 2024?** A: The overall market valuation was $1948.8 Million in 2024. **Q: What is the projected market valuation for the anti-VEGF market in China by 2035?** A: The projected valuation for 2035 is $3089.2 Million. **Q: What is the expected CAGR for the anti-VEGF market in China during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 4.28%. **Q: Which product segment had the highest valuation in the anti-VEGF market in 2024?** A: Eylea had the highest valuation, ranging from $800.0 Million to $1200.0 Million. **Q: What is the valuation range for the Lucentis product segment in the anti-VEGF market?** A: The valuation range for Lucentis is between $600.0 Million and $900.0 Million. **Q: How does the Beovu product segment perform in terms of valuation?** A: Beovu's valuation ranges from $548.8 Million to $989.2 Million. **Q: What disease segment had the highest valuation in the anti-VEGF market in 2024?** A: Diabetic Retinopathy had the highest valuation, ranging from $600.0 Million to $950.0 Million. **Q: What is the valuation range for the Age-Related Macular Degeneration disease segment?** A: The valuation range for Age-Related Macular Degeneration is between $448.8 Million and $739.2 Million. **Q: Which key players are leading the anti-VEGF market in China?** A: Key players include Regeneron Pharmaceuticals, Roche Holding, Novartis, Bayer AG, Pfizer Inc., Amgen Inc., Eli Lilly and Company, and Santen Pharmaceutical. **Q: What is the valuation range for the Retinal Vein Occlusion disease segment in the anti-VEGF market?** A: The valuation range for Retinal Vein Occlusion is between $400.0 Million and $600.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-anti-vegf-market-52173*